Assaf Dotan - research works

Despite treatment with three intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, the CNV demonstrated limited response and progressive enlargement, leading to poor final visual outcome.

The classification data set contained 330 images, and the localization data set included 659 images.

For GA localization, YOLOv8-Large achieved 91% sensitivity, 91% precision, IoU of 84%, and DICE coefficient of 88%.

Mean age was 86.72 ± 7.18.

Third of the patients improved in ≥2 lines from presentation, all in the group of the pneumatic and TPA displacement.

There was no statistical difference between the groups.

Significant associations for the development of posterior synechia were surgery for retinal detachment, longer surgery duration (>93 min) and the use of tamponade, in particular silicone oil.

Overall follow-up time was longer in the PPV group (median 4.9 vs 3.28 years, p = 0.005).

The hemorrhage was displaced in a similar percentage of patients in the tPA-and-gas group (n = 40, 78.4%) and the PPV group (n = 45, 80.4%) (p = 0.816).

Visual acuity (in LogMAR) was similar in the two groups prior to the diagnosis of subretinal hemorrhage but better in the tPA-and-gas group at the end of follow-up (p < 0.001).

The study included 68 eyes of 58 patients.

Among them, 24 eyes were treatment-naïve, and the remaining eyes had received a mean of 19.6 injections.

Immature lesions were more associated with treatment-naïve eyes and hyper-mature lesions were associated with previously treated eyes (p = 0.005).

Vascular density of the neovascular membrane was higher in the treatment-naïve group (p = 0.036) and the average MNV area was similar between the 2 groups (p = 0.683).

The most common indications for surgery in the NPDR group were ERM (67%) and rhegmatogenous retinal detachment (12.5%), while in the PDR group, indications were vitreous hemorrhage (56%) and tractional retinal detachment (19%).

There were no statistically significant differences in intra- and postoperative complication rates between the NPDR and PDR groups, even after adjusting for confounders; patient age at surgery and indication for surgery.

In the study group, staining for tPA was detected in the deep retinal layers in all eyes.

The staining was deeper and more intense at 3 and 24 h than at 48 h.

There was no tPA staining in the retina of eyes injected with saline.

The etiology of sustained ocular hypertension following intravitreal administration of anti-VEGF agents is yet to be unraveled.

Bevacizumab (25 mg/ml) was injected intravitreally after 3 days.

Donkey anti-human IgG labeled with Alexa Fluor(®) 488 was used for bevacizumab immunoreactivity detection.

Anti-CD31 antibody was used as a marker for Schlemm's canal endothelial cells.

At 1 day after treatment, complete clearance of the fibrin reaction was observed in 32 patients (80%) and partial clearance in 8 (20%).

Mean visual acuity improved from 0.61±0.38 logMAR before treatment to 0.45±0.37 logMAR 1 month later (p=0.06).

There were no statistically significant differences in improvement in visual acuity and fibrinolysis rate by time of r-tPA injection after surgery (10-15 days, n=16 vs 16-49 days, n=24).

There were no cases of increased intraocular pressure or endophthalmitis following the procedure.